Amphastar Pharma

Amphastar Pharmaceuticals, Inc. engages in developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, and insulin active pharmaceutical ingredient. It operates through Finished Pharmaceutical Products and Active Pharmaceutical Ingredients Products segments. The Finished Pharmaceutical Products segment manufactures, markets, and distributes Primatene Mist, enoxaparin, naloxone, phytonadione, lidocaine, and other critical and non-critical care drugs. The Active Pharmaceutical Ingredients Products segment offers RHI API and porcine insulin API for external customers and internal product development. The company was founded by Zi-Ping Luo and Yong Feng Zhang on February 29, 1996 and is headquartered in Rancho Cucamonga, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amphastar Pharma excels in Q4 with strong revenue growth and product success

Amphastar Pharma's Q4 2022 performance reflects strong revenue growth, profitability, and product success, positioning the company well for future growth.
The company's focus on high-margin products, FDA approvals, and strategic investments in marketing and R&D underscore its commitment to innovation and market competitiveness.
While facing challenges in sustaining growth and managing costs, Amphastar Pharma has opportunities for expansion through product development, market penetration, and strategic initiatives.

Amphastar Pharma excels in Q1 2023, eyes growth opportunities

Amphastar Pharma's Q1 2023 showcased robust financial performance, driven by revenue growth and strategic product initiatives.
While facing challenges in market dynamics and margin management, the company is well-positioned to capitalize on growth opportunities.
With a focus on innovation, market expansion, and financial strength, Amphastar Pharma demonstrates resilience and potential for sustained success.

Amphastar Pharma excels in Q2 with revenue growth and innovation

Amphastar Pharma's Q2 2023 performance reflects strong revenue growth, improved profitability, and operational efficiency, underpinned by robust sales across key products.
While facing challenges such as FDA approval delays and pipeline setbacks, the company's strategic focus on proprietary products and innovation presents opportunities for sustained growth.
By capitalizing on market demand, enhancing margins, and advancing its product pipeline, Amphastar is poised to navigate challenges and capitalize on opportunities for long-term success.

Amphastar Pharma excels in Q3 with robust revenue growth

Amphastar Pharma delivered impressive financial results in Q3 2023, marked by significant revenue growth and profitability improvements.
While facing challenges in sustaining rapid sales growth and managing debt obligations, the company's strategic focus on product expansion and market presence presents growth opportunities.
Overall, Amphastar Pharma's strong performance, diverse product portfolio, and financial stability position it well for future growth and value creation for stakeholders.

Amphastar Pharma excels in Q4 2023, eyes growth opportunities

Amphastar Pharma's Q4 2023 performance reflects robust growth in revenues, profit, and net income, driven by strategic focus and product demand.
While facing challenges like lower gross margins and capacity expansions, the company is poised for growth through innovation and market opportunities.
Opportunities lie in R&D advancements, product launches, and financial strength, positioning Amphastar Pharma for continued success and expansion.

Amphastar Pharma excels in Q1 2024, eyes growth through innovation

Amphastar Pharma's Q1 2024 showcases strong financial performance and strategic focus on product innovation and market expansion. While facing challenges in pricing and regulatory landscape, the company is poised for growth through new product launches and market penetration strategies.

Amphastar Pharma reports revenue growth amidst margin challenges and regulatory hurdles

Amphastar Pharma's Q3 performance showed revenue growth driven by key products.
While facing challenges in net income and margins, the company aims for sustainable growth.
Opportunities lie in product launches, market expansion, and regulatory progress.
Overall, Amphastar Pharma navigates financial challenges with strategic initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

RANCHO CUCAMONGA, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate Communications, Tony Marrs, Sr. V.P Regulatory Affairs and Clinical Operations, and Jacob Liawatidewi, Executive V.P. Corporate Administration Center and Sales & Marketing, will participate in an Analyst-Moderated fireside chat at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 2:30 pm Eastern time.

Amphastar Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

Amphastar Pharmaceuticals, Inc. (AMPH) Management on Q1 2021 Results - Earnings Call Transcript

RANCHO CUCAMONGA, Calif., May 07, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced the restructuring of its Chinese subsidiaries, primarily Amphastar Nanjing Pharmaceuticals Inc. (“ANP”). As part of the restructuring, Amphastar will buyback 26% of ANP's equity currently held by third parties. In addition, ANP will spin-off its Chinese subsidiary, Nanjing Hanxin Pharmaceutical Technology Co., Ltd. and Hanxin's subsidiaries (collectively, “Hanxin”). The restructuring is subject to regulatory approval, and the total cash payment by Amphastar for this restructuring will be approximately $29 million.

Amphastar Announces Buyback of 26% of the Equity in its ANP Subsidiary and Spin-off its Hanxin Subsidiary

Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) rose in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 58.82% over the past year to $0.27, which beat the estimate of $0.18.

Recap: Amphastar Pharmaceuticals Q1 Earnings

Reports Net Revenues of $103.0 Million for the Three Months Ended March 31, 2021

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2021

RANCHO CUCAMONGA, Calif., May 03, 2021 (GLOBE NEWSWIRE) --  Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the U.S. Food and Drug Administration (“FDA”) approved the Company's Abbreviated New Drug Application (“ANDA”) for Morphine Sulfate injection 1mg/mL in the 30mL Pump-Jet® Prefilled Syringe System. It is indicated for the management of pain severe enough to require use of an opioid analgesic by Patient-Controlled Analgesia (PCA), only for use with a compatible Alaris® infusion device, and for which alternative treatments are inadequate. For the past 30 years, the company has sold and marketed the product under the “grandfather” exception to the FDA's “Prescription Drug Wrap-Up” program. Net revenues for the Company's Morphine injection for the year ended December 31, 2020, were $2.3 million.

Amphastar Pharmaceuticals Receives FDA Approval for Morphine Sulfate Injection

Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amphastar Pharmaceuticals (AMPH) to Report Q1 Results: Wall Street Expects Earnings Growth

RANCHO CUCAMONGA, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its first quarter of 2021 ended March 31, 2021, after the market closes on Thursday, May 6th, 2021, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.

Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 6th, 2021

Bausch Health Companies Inc

Dr. Reddy's Labs

3 Generic Drug Stocks to Watch Amid COVID-Related Recovery

RANCHO CUCAMONGA, Calif., April 06, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, Dan Dischner, V.P of Corporate Communications and HR, Tony Marrs, Sr. V.P Regulatory Affairs and Clinical Operations, and Jacob Liawatidewi, Executive V.P. Corporate Administration Center and Sales & Marketing, will participate in an Analyst-Moderated fireside chat at the Needham Virtual Healthcare Conference on Tuesday, April 13, 2021 at 3:45 pm Eastern time.

Amphastar Pharmaceuticals to Present at the 20th Annual Needham Virtual Healthcare Conference

bluebird bio

Humanigen

uniQure

Humanigen, Inc. (NASDAQ: HGEN), uniQure N.V. (NASDAQ: QURE), bluebird bio, Inc. (NASDAQ: BLUE) and Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) were among the biotech gainers on Monday.

Why Humanigen, uniQure, bluebird bio, Amphastar Are Rallying Monday

The stock price of Amphastar Pharmaceuticals Inc (NASDAQ: AMPH) increased by over 5% pre-market. This is why it happened.

AMPH Stock Price Increased Over 5% Pre-Market: Why It Happened

RANCHO CUCAMONGA, Calif., March 29, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the U.S. Food and Drug Administration (“FDA”) approved the Company's Abbreviated New Drug Application (“ANDA”) for Dextrose injection 50% in the 50 mL Luer-Jet® Prefilled Syringe System. For the past 40 years, the company has sold and marketed the product under the “grandfather” exception to the FDA's “Prescription Drug Wrap-Up” program. Net revenues for the Company's Dextrose injection for the year ended December 31, 2020, were $7.6 million.

Amphastar Pharmaceuticals Receives FDA Approval for Dextrose Injection

Amphastar Pharmaceuticals, Inc. (AMPH) Management on Q4 2020 Results - Earnings Call Transcript

Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 128.57% year over year to $0.16, which beat the estimate of $0.14.

Recap: Amphastar Pharmaceuticals Q4 Earnings

Reports Net Revenues of $95.9 Million for the Three Months Ended December 31, 2020 Reports Net Revenues of $95.9 Million for the Three Months Ended December 31, 2020

Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2020

RANCHO CUCAMONGA, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its fourth quarter of 2020 ended December 31, 2020, after the market closes on Monday, March 15th, 2021, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.

Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on March 15th, 2021

RANCHO CUCAMONGA, Calif., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, Dan Dischner, V.P of Corporate Communications and HR, Tony Marrs, Sr. V.P Regulatory Affairs and Clinical Operations, and Jacob Liawatidewi, Executive V.P. Corporate Administration Center and Sales & Marketing, will participate in an Analyst-Moderated fireside chat at the Raymond James 2021 Institutional Healthcare Conference on Tuesday, March 2, 2021 at 1:20 pm Eastern time.

Amphastar Pharmaceuticals to Present at the Raymond James 2021 Institutional Healthcare Conference

Evoqua Water Technologies

Barings BDC Inc

Biohaven Pharmaceutical Hld

Colfax

Crh Medical

Global Blood Therapeutics

Hannon Armstrong Sustainable Infrastructure Capital

Houghton Mifflin Harcourt

Lexicon Pharmaceuticals

MannKind

Nektar Therapeutics

Nano-X Imaging

ObsEva

Personalis Inc

PIMCO Corporate & Income Opportunity Fund

Construction Partners

Surgery Partners

SP Plus

Takeda Pharmaceutical

Cohen & Steers Infrastructure Fund Inc

Xerium Technologies

A recap for my 20/20 Vision is offered for my readers. I will share my concerns about the current market conditions.

Final Update For My 20/20 Vision For 2020 Dividend Paying Stocks

RANCHO CUCAMONGA, Calif., Dec. 29, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc., (NASDAQ: AMPH) announced that the U.S. Food and Drug Administration (“FDA”) has approved its Abbreviated New Drug Application (“ANDA”) for Glucagon for Injection Emergency Kit, 1 mg. Glucagon is indicated for the treatment of severe hypoglycemia and is also used as a diagnostic aid. Amphastar's newly approved synthetic peptide product was determined by the FDA to be bioequivalent and therapeutically equivalent to Eli Lilly's Glucagon Emergency Kit for Low Blood Sugar, which has a recombinant DNA (rDNA)-origin.

Amphastar Announces Approval for Glucagon for Injection Kit, 1mg

Investors need to pay close attention to Amphastar (AMPH) stock based on the movements in the options market lately.

Do Options Traders Know Something About Amphastar (AMPH) Stock We Don't?

Amneal Pharmaceuticals

Biogen

Horizon Pharma

Phibro Animal Health

Supernus Pharmaceuticals

These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q1 2021.

Top Pharmaceutical Stocks for Q1 2021

Amphastar Pharmaceuticals, Inc. (AMPH) Management on Q3 2020 Results - Earnings Call Transcript

Amphastar Pharmaceuticals' (AMPH) Management on Q3 2020 Results - Quick Version Earnings Call Transcript

Amphastar (AMPH) delivered earnings and revenue surprises of 15.39% and -8.13%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

News for Amphastar Pharma Stock (AMPH)